Insights into the Evolving Roles of Circular RNAs in Cancer.
biomarkers
ceRNAs
circRNA
circRNA therapeutics
exosomal circRNA
fusion circRNA
miRNAs
molecular biology of cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Aug 2021
20 Aug 2021
Historique:
received:
29
07
2021
revised:
17
08
2021
accepted:
18
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
The majority of RNAs transcribed from the human genome have no coding capacity and are termed non-coding RNAs (ncRNAs). It is now widely accepted that ncRNAs play key roles in cell regulation and disease. Circular RNAs (circRNAs) are a form of ncRNA, characterised by a closed loop structure with roles as competing endogenous RNAs (ceRNAs), protein interactors and transcriptional regulators. Functioning as key cellular regulators, dysregulated circRNAs have a significant impact on disease progression, particularly in cancer. Evidence is emerging of specific circRNAs having oncogenic or tumour suppressive properties. The multifaceted nature of circRNA function may additionally have merit as a novel therapeutic target, either in treatment or as a novel biomarker, due to their cell-and disease-state specific expression and long-term stability. This review aims to summarise current findings on how circRNAs are dysregulated in cancer, the effects this has on disease progression, and how circRNAs may be targeted or utilised as future potential therapeutic options.
Identifiants
pubmed: 34439334
pii: cancers13164180
doi: 10.3390/cancers13164180
pmc: PMC8391132
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : 95519935
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/T00021X/1
Pays : United Kingdom
Références
Mol Ther Nucleic Acids. 2020 Jun 5;20:25-33
pubmed: 32145677
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
Ann Transl Med. 2020 Nov;8(21):1375
pubmed: 33313120
Adv Exp Med Biol. 2018;1087:67-79
pubmed: 30259358
Mol Cancer. 2020 Mar 14;19(1):58
pubmed: 32171304
Nat Rev Drug Discov. 2014 Oct;13(10):759-80
pubmed: 25233993
Cell. 2019 Feb 7;176(4):869-881.e13
pubmed: 30735636
Oncol Rep. 2015 Jan;33(1):3-18
pubmed: 25369839
EBioMedicine. 2019 Feb;40:432-445
pubmed: 30630697
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Nat Commun. 2018 Oct 26;9(1):4475
pubmed: 30367041
Cell Death Differ. 2013 Dec;20(12):1603-14
pubmed: 24212931
Int J Oncol. 2018 Oct;53(4):1752-1762
pubmed: 30015883
Mol Cell. 2014 Oct 2;56(1):55-66
pubmed: 25242144
Nat Struct Mol Biol. 2015 Mar;22(3):256-64
pubmed: 25664725
J Exp Clin Cancer Res. 2020 Jun 3;39(1):101
pubmed: 32493490
Biomed Res Int. 2020 Jan 22;2020:1487609
pubmed: 32090067
Oncogene. 2019 Nov;38(47):7197-7199
pubmed: 31616060
Cell Res. 2015 Aug;25(8):981-4
pubmed: 26138677
Life Sci. 2019 Dec 15;239:116984
pubmed: 31647948
Front Cell Dev Biol. 2020 Nov 25;8:581558
pubmed: 33324638
Mol Ther. 2020 Jun 3;28(6):1506-1517
pubmed: 32304667
Signal Transduct Target Ther. 2020 Aug 5;5(1):145
pubmed: 32759948
Int J Genomics. 2016;2016:4503840
pubmed: 27965971
Wiley Interdiscip Rev RNA. 2015 Sep-Oct;6(5):563-79
pubmed: 26230526
Clin Cancer Res. 2018 Dec 15;24(24):6319-6330
pubmed: 30305293
Biochimie. 2019 Sep;164:45-52
pubmed: 31265859
Cell Metab. 2014 Sep 2;20(3):433-47
pubmed: 25043816
Carcinogenesis. 2010 Jan;31(1):27-36
pubmed: 19752007
Cell Death Differ. 2019 Jul;26(7):1346-1364
pubmed: 30341421
Cell. 2015 Mar 12;160(6):1125-34
pubmed: 25768908
Mol Cell. 2019 May 2;74(3):508-520.e4
pubmed: 30902547
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):247-260
pubmed: 29928954
Mol Cancer. 2019 May 22;18(1):98
pubmed: 31118036
Nat Commun. 2018 Jul 6;9(1):2629
pubmed: 29980667
Clin Chem. 2015 Jan;61(1):221-30
pubmed: 25376581
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Mol Cancer. 2020 Feb 15;19(1):30
pubmed: 32059672
Nature. 2009 Apr 9;458(7239):719-24
pubmed: 19360079
Mol Cell. 2015 Jun 4;58(5):870-85
pubmed: 25921068
Int J Cancer. 2019 May 15;144(10):2501-2515
pubmed: 30412280
Front Cell Dev Biol. 2021 Apr 12;9:646864
pubmed: 33912560
Nat Rev Genet. 2006 Jan;7(1):21-33
pubmed: 16369569
PLoS One. 2015 Oct 20;10(10):e0141214
pubmed: 26485708
Cell Biol Int. 2014 Sep;38(9):1076-9
pubmed: 24798520
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
pubmed: 12434020
Genome Biol. 2018 Dec 11;19(1):218
pubmed: 30537986
J Exp Clin Cancer Res. 2018 Jul 31;37(1):177
pubmed: 30064461
Cell Death Dis. 2021 Apr 28;12(5):420
pubmed: 33911067
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
Sci Rep. 2019 Feb 22;9(1):2564
pubmed: 30796328
Int J Mol Sci. 2017 Mar 02;18(3):
pubmed: 28257101
RNA. 2013 Feb;19(2):141-57
pubmed: 23249747
Cell. 2016 Aug 11;166(4):1055-1056
pubmed: 27518567
Mol Cell. 2018 Aug 2;71(3):428-442
pubmed: 30057200
Mol Cell. 2017 Apr 6;66(1):9-21.e7
pubmed: 28344080
Int J Oncol. 2019 Dec;55(6):1183-1193
pubmed: 31661122
Adv Drug Deliv Rev. 2015 Jan;81:117-27
pubmed: 24859534
Oncotarget. 2016 Jun 14;7(24):36366-36381
pubmed: 27119352
iScience. 2018 Jul 27;5:19-29
pubmed: 30240643
Oncogene. 2018 Nov;37(44):5829-5842
pubmed: 29973691
Biochimie. 2011 Nov;93(11):1897-904
pubmed: 21712066
Cancer Lett. 2018 Sep 28;432:237-250
pubmed: 29709702
J Biomed Sci. 2019 May 11;26(1):35
pubmed: 31078138
Theranostics. 2019 May 26;9(12):3526-3540
pubmed: 31281495
Mol Cell. 2013 Sep 26;51(6):792-806
pubmed: 24035497